Notably, tumour CD155 (the binding partner for TIGIT) expression has been linked with resistance to αPD-1 therapy in patients with metastatic melanoma [274], while expression of CD155 on cancer cells ablates CTL activation via CD226 degradation [275]. Here, TIGIT is linked to cancer.